US20130071489A1 - Methods and compositions for safe and effective treatment of erythema - Google Patents

Methods and compositions for safe and effective treatment of erythema Download PDF

Info

Publication number
US20130071489A1
US20130071489A1 US13/637,040 US201113637040A US2013071489A1 US 20130071489 A1 US20130071489 A1 US 20130071489A1 US 201113637040 A US201113637040 A US 201113637040A US 2013071489 A1 US2013071489 A1 US 2013071489A1
Authority
US
United States
Prior art keywords
erythema
topical
brimonidine
symptom
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/637,040
Other languages
English (en)
Inventor
Michael Graeber
Christian Loesche
Philip FREIDENREICH
Yin Liu
Matthew James Leoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44012352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130071489(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to US13/637,040 priority Critical patent/US20130071489A1/en
Assigned to GALDERMA RESEARCH & DEVELOPMENT SNC reassignment GALDERMA RESEARCH & DEVELOPMENT SNC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOESCHE, CHRISTIAN, FREIDENREICH, PHILIP, GRAEBER, MICHAEL, LEONI, MATTHEW JAMES, LIU, YIN
Publication of US20130071489A1 publication Critical patent/US20130071489A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • Erythema is a skin condition characterized by redness of the skin. It occurs with any skin injury, infection, or inflammation. It can also occur as a reaction to medications, illness or emotions. It can further occur for reasons currently unknown. Erythema is difficult to treat. Currently available treatments for erythema mainly treat the underlying diseases and avoid known triggers. These treatments are of limited effectiveness, particularly for erythema with unknown causes.
  • Brimonidine a selective ⁇ 2-adrenergic agonist
  • IOP intraocular pressure
  • OHT ocular hypertension
  • the most common side effects associated with brimonidine therapy are dry mouth, fatigue/drowsiness, headache, mild hyperemia, blurred vision and foreign body sensation.
  • Hypertension, palpitations and syncope have been reported by less than 3% patients in clinical trials involving brimonidine ophthalmic treatment. See McGhie, Journal of the Pharmacy Society of Wisconsin , May/June 2001, at World Wide Web: pswi.org/professional/pharmaco/brimonidine.pdf, and references therein.
  • results from the dose-ranging study in patients with glaucoma or ocular hypertension showed that although 0.5% (w/w) had higher efficacy in the early phase of treatment, the 0.5% (w/w) and 0.2% (w/w) had similar efficacy after two weeks of treatment, and that 0.5% (w/w) had more systemic and ocular side effects than 0.2% (w/w). See, e.g., Walters, Survey of Ophthalmology, 1996, 41: S19-S26).
  • Ophthalmic formulations containing 0.2% (w/w) brimonidine have been used for chronic applications to treat glaucoma and ocular hypertension, while that containing 0.5% (w/w) brimonidine has been only used for acute therapy for the prevention of postoperative intraocular pressure spikes.
  • ophthalmic formulations containing lower concentrations of brimonidine e.g., 0.15% (w/w) or 0.1% (w/w) have been subsequently developed and used for chronic ophthalmic applications.
  • Brimonidine has been reported to be useful in treating erythema caused by rosacea. See, e.g., U.S. Ser. No. 10/853,585 to DeJovin et al. To ensure the safety and avoid unacceptable side effects, a previous clinical study used 0.2% (w/w) brimonidine tartrate as the “high” dosage for treating erythema. See US 2009/0061020 to Theobald et al.
  • brimonidine topical administration of brimonidine to a skin area affected by erythema or a related symptom resulted in significantly less systemic exposure to brimonidine than topical ophthalmic application of brimonidine. It has been found that although systemic exposure increased with the applied dose of brimonidine, statistical analysis showed that the increase in systemic exposure (C max ) was not dose proportional, e.g., the increase in the mean C max was much less than the increase in the dose.
  • a higher concentration of brimonidine such as about 0.3% (w/w) to about 10% (w/w) can now be used in improved methods and compositions for safe and effective treatment of erythema or a symptom associated therewith.
  • embodiments of the present invention relate to a method of providing a safe and effective treatment of erythema or a symptom associated therewith in a subject.
  • the method comprises topically administering to a skin area affected by the erythema or the symptom a topical composition, which comprises about 0.3% to about 10% by weight brimonidine and a pharmaceutically acceptable carrier, wherein the topical administration effects a serum or plasma profile of brimonidine having a mean C max of about 54 ⁇ 28 pg/mL or less and a mean AUC 0-24 hr of about 568 ⁇ 277 pg ⁇ hr/mL or less.
  • embodiments of the present invention relate to a method of producing a packaged product for providing a safe and effective treatment of erythema or a symptom associated therewith in a subject.
  • the method comprises:
  • a topical composition comprising about 0.3% to about 10% by weight brimonidine and a pharmaceutically acceptable carrier;
  • embodiments of the present invention relate to a topical gel composition for providing a safe and effective treatment of erythema or a symptom associated therewith in a subject.
  • the topical gel composition comprises:
  • topical administration of the topical gel composition to a skin area affected by the erythema or the symptom effects a serum or plasma profile of brimonidine having a mean C max of about 54 ⁇ 28 pg/mL or less and a mean AUC 0-24 hr of about 568 ⁇ 277 pg ⁇ hr/mL or less.
  • the topical composition used in or encompassed by embodiments of the present invention comprises about 0.4% (w/w) to about 0.6% (w/w) brimonidine tartrate.
  • the erythema is erythema of rosacea.
  • FIG. 1 illustrates composite success on Day 1, Day 15 and Day 29 after the initial treatment, using last observation carried forward (LOCF) approach in the intent to treat (ITT) population;
  • LOCF last observation carried forward
  • FIG. 2 illustrates CEA success on Day 1, Day 15 and Day 29 after the initial treatment, using LOCF approach in the ITT population
  • FIG. 3 illustrates PSA-5 success on Day 1, Day 15 and Day 29 after the initial treatment using LOCF approach in the ITT population.
  • erythema or a symptom associated therewith is intended to encompass any type or classification of abnormal skin redness associated with or resulting from rosacea, e.g., erythema or a symptom associated therewith in a patient with rosacea.
  • a major symptom of rosacea is erythema, which is a skin disorder that generally affects the cheeks, nose, chin, and forehead of a patient.
  • erythema or a symptom associated therewith encompasses different degrees or grades of erythema or a symptom associated therewith, from mild to severe.
  • erythema or a symptom associated therewith can be rated by a clinician based on Clinician's Erythema Assessment Score (CEA) on a scale from 0 to 4, with 0 being clear skin with no signs of erythema; 1 being almost clear, slight redness; 2 being mild erythema, definite redness; 3 being moderate redness; and 4 being severe redness.
  • CEA Clinician's Erythema Assessment Score
  • Erythema or a symptom associated therewith can also be rated by a patient based on Patient's Self Assessment (PSA, also called PSA-5 herein) on a scale from 0 to 4, with 0 being no redness; 1 being very mild redness; 2 being mild redness; 3 being moderate redness and 4 being severe redness.
  • PSA Patient's Self Assessment
  • a skin area that is affected by erythema or that is prone to be affected by erythema can be identified using any diagnostic signs or means known in the art, and can be treated by methods according to embodiments of the present invention.
  • the efficacy of the treatment can be measured using method known in the art.
  • the efficacy can be measured by the grades of improvement as evaluated by CEA, PSA or the combination of CEA and PSA, and the duration of the improvement.
  • brimonidine refers to the compound (5-bromo-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine having the structure of formula (I):
  • any pharmaceutically acceptable salt of the compound including, but not limited to, brimonidine tartrate.
  • pharmaceutically acceptable salt(s) means those salts of a compound of interest that are safe and effective for topical use in mammals and that possess the desired biological activity.
  • Pharmaceutically acceptable salts include salts of acidic or basic groups present in the specified compounds.
  • Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts.
  • Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and diethanolamine salts.
  • topically administrable composition means any formulation or composition which is pharmaceutically and/or cosmetically acceptable for topical delivery of the specified compounds according to embodiments of the invention.
  • exemplary forms of formulation that can be used for topical administration in embodiments of the present invention include, but are not limited to, sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions and suspensions.
  • topically administrable composition as used herein, also encompasses locally applied and locally acting formulations such as formulations for use with implants, injections, or patches.
  • topically administrable composition will depend on several factors, including, but not limited to, the nature of the symptoms to be treated or prevented, the physiochemical characteristics of the particular compound to be administered and of other excipients present, their stability in the formulation, the aesthetics of any given formulation, available manufacturing equipment, and cost constraints.
  • composition is intended to encompass a product comprising the specified ingredient in the specified amount, as well as any product which results, directly or indirectly, from combinations of the specified ingredient in the specified amount.
  • the term “subject” means any animal, preferably a mammal, most preferably a human, to whom will be or has been administered compounds or topical formulations according to embodiments of the invention.
  • a subject is in need of, or has been the object of observation or experiment of, treatment or prevention of erythema or a symptom associated therewith.
  • the term “instructions” when used in the context of a packaged product includes a publication, a recording, a diagram or any other medium of expression which can be used to communicate the usefulness of the packaged product for its designated use.
  • the instructions can, for example, be affixed to or included within a container for the packaged product.
  • treatment refers to an amelioration, prophylaxis, or reversal of erythema or a symptom associated therewith, for example, by lessening or delaying the onset of the redness of the skin affected by the erythema or the symptom.
  • a “safe and effective amount of brimonidine” means the amount of brimonidine that is effective to treat erythema or a symptom associated therewith, without causing unacceptable drug related adverse events, when administered to a subject.
  • unacceptable drug related adverse events shall all mean harm or undesired outcome associated with or caused by a proposed use of a drug, and the harm or undesired outcome reaches such a severity that a regulatory agency deems the drug unacceptable for the proposed use.
  • topical administration of a safe and effective amount of brimonidine such as a topical composition comprising about 0.3% to about 10% by weight of brimonidine, to a skin area affected by erythema or a symptom associated therewith, provides effective treatment of erythema or a symptom associated therewith, without causing unacceptable drug related adverse events.
  • topical administration of a topical composition comprising increasing concentration of brimonidine to a skin area affected by erythema or a symptom associated therewith resulted in a clear dosage responsive increase in the efficacy and an increase in the systemic exposure.
  • embodiments of the present invention relate to a method of providing a safe and effective treatment of erythema or a symptom associated therewith in a subject, comprising topically administering to a skin area affected by the erythema or the symptom a topical composition comprising about 0.3% to about 10% by weight brimonidine and a pharmaceutically acceptable carrier, wherein the topical administration effects a serum or plasma profile of brimonidine having a mean C max of about 54 ⁇ 28 pg/mL or less and a mean AUC 0-24 hr of about 568 ⁇ 277 pg ⁇ hr/mL or less.
  • the mean C max and the mean AUC 0-24 hr correspond to the serum or plasma profile of brimonidine after ophthalmic treatment with 0.2% (w/w) brimonidine tartrate eye drops as recommended in the label of the ophthalmic product.
  • the onset of noticeable effect i.e., at least 1-grade improvement of the erythema or the symptom
  • the noticeable effect is then progressed to maximum improvement, which includes 2-grade of improvement of the erythema or the symptom that lasts for a sustained period of time.
  • the maximum improvement then declines to noticeable effect, which then disappears.
  • the grades of improvement of the erythema or the symptom can be evaluated by Clinician's Erythema Assessment Score (CEA), a Patient's Self Assessment (PSA), or a combination of CEA and PSA.
  • CEA Clinician's Erythema Assessment Score
  • PSA Patient's Self Assessment
  • the topical administration of a topical composition comprising about 0.3% (w/w) to about 10% (w/w) brimonidine to a skin area affected by erythema or a symptom associated therewith results in significantly more effective treatment of the erythema and the symptom than a vehicle control for reduction of facial erythema associated with rosacea as measured by a 12 hour success profile evaluated on both CEA and PSA scales, without causing any unacceptable adverse effect.
  • the 12 hour success profile comprises at least 1-grade improvement of the erythema or the symptom.
  • the topical administration of a topical composition comprising about 0.3% (w/w) to about 10% (w/w) brimonidine to a skin area affected by erythema or a symptom associated therewith resulted in significantly more reduction of facial erythema associated with rosacea compared to a vehicle control as measured by a 12 hour success profile evaluated on both CEA and PSA scales, without causing any unacceptable adverse effect.
  • the 12 hour success profile comprises a noticeable effect of 1-grade improvement of the erythema or the symptom and about 1 hour to about 8 hours of a 2-grade improvement of the erythema or the symptom.
  • the 2-grade improvement lasts, for example, at least about 6 hours, at least about 5 hours, at least about 4 hours, at least about 3 hours, at least about 2 hours or at least about 1 hour, depending on the applied dose, the particular subject, the severity and complications of erythema being treated, etc.
  • the 12 hour success profile comprises a noticeable effect of 1-grade improvement of the erythema or the symptom and about 2 hours to about 7 hours of a 2-grade improvement of the erythema or the symptom.
  • the 12 hour success profile comprises a noticeable effect of 1-grade improvement of the erythema or the symptom and about 3 hours to about 6 hours of a 2-grade improvement of the erythema or the symptom.
  • the 12 hour success profile comprises a noticeable effect of 1-grade improvement of the erythema or the symptom and about 2 hours to about 5 hours of a 2-grade improvement of the erythema or the symptom.
  • the erythema is erythema of rosacea.
  • the topically administrable composition comprises about 0.3%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5% or 10.0%, by weight of brimonidine, such as brimonidine tartrate.
  • brimonidine such as brimonidine tartrate.
  • the topically administrable composition comprises about 0.4%, about 0.45%, about 0.5%, about 0.55% or about 0.6%, by weight of brimonidine, such as brimonidine tartrate.
  • the topical composition comprises about 0.5% by weight of brimonidine, such as about 0.5% by weight of brimonidine tartrate.
  • the topically administrable compositions of the invention can be topically applied directly to the affected area in any conventional manner known in the art, e.g., by dropper, applicator stick, or cotton swab, as a mist via an aerosol applicator, via an intradermal or transdermal patch, or by simply spreading a formulation of the invention onto the affected area with fingers, a sponge, a pad, or wipes.
  • the amount of a topical formulation of the invention applied to the affected skin area ranges from about 0.0001 g/cm 2 of skin surface area to about 0.05 g/cm 2 , preferably, 0.002 g/cm 2 to about 0.005 g/cm 2 of skin surface area.
  • one to four applications per day are recommended during the term of treatment.
  • the topical composition is topically applied to the affected skin area once daily.
  • Methods of the present invention can be used in conjunction with one or more other treatments and medications for erythema or a symptom associated therewith, such as the medications used to treat the underlying disease that causes erythema, antihistamines to control itching, antibiotics, corticosteroids, intravenous immunoglobulins, acetaminophen, etc.
  • the other medicament or treatment can be administered to the subject simultaneously with, or in a sequence and within a time interval of, the administration of brimonidine, such that the active ingredients or agents can act together to treat or prevent erythema and symptoms associated therewith.
  • the other medicament or treatment and brimonidine can be administered in the same or separate formulations at the same or different times, i.e., before or after. Any suitable route of administration can be employed to deliver the additional treatment or medication.
  • Another aspect of the invention relates to a packaged product for providing a safe and effective treatment of erythema or a symptom associated therewith in a subject.
  • the method comprises:
  • a topical composition comprising about 0.3% to about 10% by weight brimonidine and a pharmaceutically acceptable carrier;
  • topical administration effects a serum or plasma profile of brimonidine having a mean C max of about 54 ⁇ 28 pg/mL or less and a mean AUC 0-24 hr of about 568 ⁇ 277 pg ⁇ hr/mL or less.
  • the topical composition is contained within one suitable container, such as a dropper, a jar, or a tube with a suitable small orifice size, such as an extended tip tube, made of any pharmaceutically suitable material.
  • the topical formulations according to embodiments of the invention can be filled and packaged into a plastic squeeze bottle or tube.
  • Suitable container-closure systems for packaging a topical formulations of the invention are commercially available for example, from Wheaton Plastic Products, 1101 Wheaton Avenue, Millville, N.J. 08332.
  • an applicator can be provided in or attached to the container, or separately from the container.
  • the instructions are, for example, a pamphlet or package label.
  • the instructions explain how to administer topical formulations of the invention, in an amount and for a period of time sufficient to provide a safe and effective treatment of erythema or a symptom associated therewith.
  • the instructions include, for example, the dosage and administration instructions, the topical formulation's composition, the clinical pharmacology, drug resistance, pharmacokinetics, absorption, bioavailability, and contraindications.
  • the topical gel composition comprises:
  • topical administration of the topical gel composition to a skin area affected by the erythema or the symptom effects a serum or plasma profile of brimonidine having a mean C max of about 54 ⁇ 28 pg/mL or less and a mean AUC 0-24 hr of about 568 ⁇ 277 pg ⁇ hr/mL or less.
  • the topically administrable composition are prepared by mixing a pharmaceutically acceptable carrier with the safe and effective amount of brimonidine according to known methods in the art, for example, methods provided by standard reference texts such as, REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1577-1591, 1672-1673, 866-885(Alfonso R. Gennaro ed. 19th ed. 1995); Ghosh, T. K.; et al. TRANSDERMAL AND TOPICAL DRUG DELIVERY SYSTEMS (1997), both of which are hereby incorporated herein by reference.
  • the topical gel composition comprises about 0.4% to about 0.6% by weight of brimonidine, more preferably, 0.5% by weight of brimonidine tartrate.
  • Suitable gelling agents known in the art can be used in the present invention.
  • suitable gelling agents are disclosed in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1517-1518 (Alfonso R. Gennaro ed. 19th ed. 1995), which is hereby incorporated herein by reference.
  • the gelling agents used in embodiments of the present invention include, but are not limited to, one or more hydrophilic and hydroalcoholic gelling agents used in the cosmetic and pharmaceutical industries.
  • the hydrophilic or hydroalcoholic gelling agent comprises “CARBOPOL®” (B.F.
  • the preferred compositional weight percent range for “CARBOPOL®” is between about 0.5% to about 2%, while the preferred weight percent range for “NATROLSOL®” and “KLUCEL®” is between about 0.5% to about 4%.
  • the preferred compositional weight percent range for both “HYPAN®” and “STABILEZE®” is between 0.5% to about 4%.
  • Other preferred gelling agents include hydroxyethylcellulose, cellulose gum, MVE/MA decadiene crosspolymer, PVM/MA copolymer, glycerine polyacrylate, or a combination thereof.
  • carbomers examples include, but are not limited to, Carbomer 910, 934P, 940, 941, 980 and 1342, and Carbopol® 974P and Carbopol® 980.
  • the carbomer is Carbomer 934P or Carbopol® 974P, and Carbopol® 980.
  • the amount of the carbomer in the composition is about 0.5%, 0.6%, 0.7%, 0.8%, 0.85%, 0.95%, 1.05%, 1.15%, 1.25%, 1.35%, 1.45%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% or 2.0% (w/w).
  • Polyol gel formulations with various ingredients solubilized therein have been used to minimize irritation when applied to the skin of a subject, while ensuring bioavailability of the active agent in the formulation. See Other III et al. “Gels and Jellies,” pp. 1327-1344 of Encyclopedia of Pharmaceutical Technology , vol. 3 (ed. by Swarbrick, et al, pub. by Marcel Dekker, 2002); or Pena, “Gel Dosage Forms: Theory, Formulation, and Processing,” pp. 381-388 of Topical Drug Delivery Formulations , (ed. by Osborne et al., pub. by Marcel Dekker, Inc., 1990).
  • Polyols in gel formulations can serve one or more functions such as solubilizing agents, moisturizers, emollients, skin humectant, skin-penetration agents, etc.
  • Suitable polyols that can be used in embodiments of the present invention include, but are not limited to, glycerine, propylene glycol, dipropylene glycol, hexylene glycol, butylene glycol, and liquid polyethylene glycols, such as polyethylene glycol 200 to 600.
  • the amount of the total polyols in the composition is about 5.0% to 30.0% (w/w), for example, about 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 10.5%, 11.0%, 11.5%, 12.0%, 12.5%, 13.0%, 13.5%, 14.0%, 14.5%, 15.0%, 17%, 20%, 25% or 30% (w/w).
  • the topical gel composition comprises a first polyol and a second polyol, such as propylene glycol and glycerine, respectively.
  • the amount of each of the first and second polyols in the composition is independently about 4 to 15%, such as 4.5% to 6.5% (w/w), for example, 4.5%, 5.0%, 5.5%, 6.0% or 6.5% (w/w).
  • the pH of the topical formulations of the invention are preferably within a physiologically acceptable pH, e.g., within the range of about 4 to about 8, preferably, of about 6 to about 7.5, and more preferably about 4.5 to 6.5.
  • a buffer is included in the aqueous topical formulation in an amount of from about 0.05 to about 1 weight percent of the formulation.
  • the topical gel composition of the present invention can include one or more other ingredients, such as a protective agent, a cosmetic agent, an adsorbent, a preservative, an antioxidant, a surfactant, a skin-penetration agent, local anesthetics, analgesics etc.
  • a protective agent such as a cosmetic agent, an adsorbent, a preservative, an antioxidant, a surfactant, a skin-penetration agent, local anesthetics, analgesics etc.
  • a topical gel composition according to embodiments of the invention further comprises water dispersible form of titanium dioxide (TiO2), preferably at an amount that is sufficient to mask the color of brimonidine or another colored ingredient in the formulation, but would not cause irritation to the skin.
  • TiO2 may cause mild irritation and reddening to the eyes, thus eye contact with the TiO2—containing topically administrable composition should be avoided.
  • Titanium dioxide imparts a whiteness to the topically administrable composition and helps to increase the opacity and reduce the transparency of the composition. Titanium dioxide absorbs, reflects, or scatters light (including ultraviolet radiation in light), which can help protect products from deterioration. Titanium dioxide can also be used as a sunscreen to protect the user from the harmful effects of ultraviolet radiation that is part of sunlight.
  • the amount of water dispersible form of titanium dioxide in the composition is about 0.04 to 0.2%, such as 0.04%, 0.0425%, 0.0525%, 0.0625%, 0.0725%, 0.0825%, 0.09%, 0.10%, 0.15%, or 0.20% (w/w).
  • Suitable preservatives include, but are not limited to, quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetrimide, dequalinium chloride, and cetylpyridinium chloride; alcoholic agents, for example, chlorobutanol, phenylethyl alcohol, and benzyl alcohol; parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben; antibacterial esters, for example, esters of parahydroxybenzoic acid; and other anti-microbial agents such as chlorhexidine, chlorocresol, benzoic acid, polymyxin, and phenoxyethanol.
  • the preservative is selected from the group consisting of sodium benzoate, phenoxyethanol, benzyl alcohol, methylparaben, imidazolidinyl urea and diazolidinyl urea.
  • the topically administrable composition according to embodiments of the invention can optionally include one or more other pharmaceutically active ingredients, including, but not limited to, medications used to treat the underlying disease that causes erythema, antihistamines to control itching, antibiotics, corticosteroids, intravenous immunoglobulins, acetaminophen, etc.
  • other pharmaceutically active ingredients including, but not limited to, medications used to treat the underlying disease that causes erythema, antihistamines to control itching, antibiotics, corticosteroids, intravenous immunoglobulins, acetaminophen, etc.
  • This example illustrates gel topical formulations that can be used in the present invention.
  • a first group of gel formulations is described in Table 1 below.
  • the pH of the formulation is adjusted to about 4.5 to 7.0.
  • the ingredients are mixed together and aqueous sodium hydroxide is slowly added to the mixture until a pH of about 4.5 to 6.5 is reached and the gel is formed.
  • the ingredients are mixed together and aqueous sodium hydroxide is slowly added to the mixture until a pH of about 4.5 to 6.5 is reached and the gel is formed.
  • Triethanolamine is added until a pH of about 5.5 to 7.0 is attained.
  • This study was a randomized, evaluator-blinded, intra-individual comparative pharmacokinetic study of brimonidine tartrate, ophthalmic solution (0.2%) and topical gel (0.07%, 0.18% and 0.50%) applied under maximal use conditions for 29 days in subjects with moderate to severe erythema associated with rosacea.
  • Major entrance criteria included clinical diagnosis of moderate to severe facial erythema associated with rosacea, CEA score ⁇ 3, and IOP level 11-21 mmHg.
  • Intra-subject comparison of topical to ophthalmic exposure following one day treatment with brimonidine tartrate ophthalmic solution 0.2% was performed.
  • a total of 102 subjects were randomized: 24, 26, 25, and 27 subjects in 0.5% Gel QD, 0.18% Gel BID, 0.18% Gel QD, and 0.07% Gel BID, respectively.
  • On the Day 1 visit one drop of brimonidine tartrate ophthalmic solution 0.2% was administered to each eye every 8 hours over a 24 hour period.
  • one gram of topical gel (0.07%, 0.18%, or 0.50% of brimonidine tartrate) was applied once (QD) or twice daily (BID) to the face of subjects for 4 weeks.
  • Blood samples for complete PK profiling were taken during the 24-hour ocular treatment (study Day 1) and during the first day of topical application (study Day 4), fifteen days of topical application (study Day 18) and after the last topical application up to 72 hours post-dose (study Day 32). Additional blood samples were collected before application (Day 10, Day 24). Brimonidine plasma concentrations were determined by using a validated LC-MS/MS method with a lower limit of quantification (LOQ) of 10 pg/mL.
  • LOQ lower limit of quantification
  • the PK parameters for brimonidine were calculated using standard non-compartmental method and C max , AUC 0-24 hr were analyzed statistically using log-transformed data. For both the differences between times administration routes and between treatment groups, the limits of the intervals were back-transformed into exponential to obtain 90% confidence intervals (90% CI) of the ratios of geometric means on the original scale. The statistical analysis was performed using all C max (BLQ values being replaced by the LOQ) and using only quantifiable AUC o-24 hr .
  • Ocular treatment Administration of brimonidine tartrate 0.2% by ophthalmic route resulted in quantifiable exposure (>10 pg/mL) in all patients receiving TID treatment.
  • the pharmacokinetic (PK) parameters of the ophthalmic solution have a mean C max of 54 ⁇ 28 pg/mL (range: 16-134 pg/mL) and a mean AUC 0-24 hr of 568 ⁇ 277 pg ⁇ hr/mL (range: 124-1490 pg ⁇ hr/mL).
  • Topical treatments Daily topical application of brimonidine Gel for 29 days resulted in quantifiable (>10 pg/mL) systemic exposure in 24%, 48%, 68% and 75% of subjects receiving brimonidine Gel 0.07% BID, 0.18% QD, 0.18% BID or 0.5% QD, respectively.
  • the mean ( ⁇ SD) C max were 13 ⁇ 9 pg/mL 17 ⁇ 20 pg/mL, 17 ⁇ 10 pg/mL, 25 ⁇ 24 pg/mL for brimonidine Gel 0.07% BID, 0.18% QD, 0.18% BID or 0.5% QD, respectively.
  • Quantifiable AUC 0-24 hr were 172 ⁇ 87 pg ⁇ hr/mL, 183 ⁇ 113 pg ⁇ hr/mL, 267 ⁇ 119 pg ⁇ hr/mL, 364 ⁇ 216 pg ⁇ hr/mL for brimonidine Gel 0.07% BID, 0.18% QD, 0.18% BID or 0.5% QD, respectively.
  • the topical systemic exposure (expressed as C max or AUC 0-24 hr ) from the skin treatment was compared to the one obtained after ocular treatment. See Table 5.
  • the Ocular/Topical ratios calculated over the entire duration of the topical treatment period were significantly lower than 1.
  • the C max mean ratio was 0.2 for 0.07% BID group, ranged from 0.2 to 0.3 for 0.18% QD and BID groups and ranged from 0.3 to 0.6 for 0.5% QD group.
  • the upper limit of the 90% confidence interval did not include 0.8 whatever the dose and dose regimen tested.
  • the highest ratio was observed in the 0.5% QD group (mean ratio 0.6, 90% CI [0.5-0.7]) after 15 days of application, but not confirmed at the end of the 29-day of topical treatment (mean ratio 0.4, 90% CI [0.3-0.4]).
  • concentrations of brimonidine higher than 0.2% (w/w) can be used for topical administration to an affected skin area for safe and effective treatment of a skin disorder.
  • Major entrance criteria included clinical diagnosis of moderate to severe facial erythema associated with Rosacea, CEA score ⁇ 3 and PSA-5 score ⁇ 3, presence of no more than 2 facial lesions, and IOP level at least 10 mmHg.
  • Qualified subjects were randomized in a 1:1:1:1:1 ratio (block size of 5) to one of the five treatment arms (0.5% QD, 0.18% BID, 0.18% QD, Vehicle BID, Vehicle QD).
  • a total of 269 subjects from 17 clinical sites were randomized to Topical Gel or Vehicle Gel: 53, 54, 54, 53, and 55 subjects in the 0.5% QD, 0.18% BID, 0.18% QD, Vehicle BID, and Vehicle QD arms, respectively. All 269 subjects were included in the ITT and Safety population, and 237 subjects were included in the PP population.
  • CEA and PSA evaluation data were collected at each clinic visit at Hours 3, 6, 9, and 12 after study drug application. Data collected at 30 minutes after study drug application comprised the secondary endpoints of CEA Initial Effect and PSA Initial Effect. Subject-reported efficacy data were collected at clinic visits and on non-clinic days during the treatment period. Safety were assessed throughout the study.
  • the primary endpoint, Composite Success is defined as a 2-grade improvement on both CEA and PSA-5 measured at Hours 3, 6, 9 and 12 on Day 29 after the treatment.
  • Statistical analysis was performed to compare each active treatment (0.5% QD, 0.18% BID and QD) vs. the corresponding Vehicle QD or Vehicle BID, respectively. Additional analyses for Composite Success on early treatment visits Day 15 and Day 1 were performed to further investigate the early treatment effect.
  • CEA-Success and PSA-5 Success were also analyzed individually.
  • the magnitudes of the CEA-Success ( FIG. 2 ) and PSA-5 ( FIG. 3 ) Success were greater in all treatment groups compared to Composite Success but the pattern of the relative effects was same as observed in Composite Success. Consistently, 0.5% QD showed the greatest effect for CEA Success and PSA-5 Success; 0.18% QD and BID showed numerically better effect compared to Vehicle QD and BID, respectively.
  • AEs related adverse events
  • the overall incidence of related adverse events (AEs) for the study was low.
  • the number of related AEs was comparable between the treatment groups, and there was no significant difference in incidence of related adverse events between active and vehicle treatment arms.
  • No severe related AEs were reported during the study.
  • brimonidine Unlike ophthalmic applications of brimonidine, where the chronic use of lower concentration of brimonidine, e.g., 0.1% (w/w), provides improved tolerability while maintaining IOP-lowering efficacy, the present clinical studies unexpectedly discovered that higher concentrations of brimonidine provide significantly improved clinical efficacy in treating erythema or related symptoms, while not causing any observable change in patient safety and tolerability as compared to lower concentrations of brimonidine.
  • concentration of brimonidine e.g. 0.1% (w/w)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US13/637,040 2010-03-26 2011-03-25 Methods and compositions for safe and effective treatment of erythema Abandoned US20130071489A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/637,040 US20130071489A1 (en) 2010-03-26 2011-03-25 Methods and compositions for safe and effective treatment of erythema

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28275410P 2010-03-26 2010-03-26
PCT/EP2011/054596 WO2011117377A2 (fr) 2010-03-26 2011-03-25 Méthodes et compositions améliorées pour le traitement sûr et efficace de l'érythème
US13/637,040 US20130071489A1 (en) 2010-03-26 2011-03-25 Methods and compositions for safe and effective treatment of erythema

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/054596 A-371-Of-International WO2011117377A2 (fr) 2010-03-26 2011-03-25 Méthodes et compositions améliorées pour le traitement sûr et efficace de l'érythème

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/097,912 Continuation US20140094469A1 (en) 2010-03-26 2013-12-05 Methods and compositions for safe and effective treatment of erythema

Publications (1)

Publication Number Publication Date
US20130071489A1 true US20130071489A1 (en) 2013-03-21

Family

ID=44012352

Family Applications (6)

Application Number Title Priority Date Filing Date
US13/072,096 Active US8513247B2 (en) 2010-03-26 2011-03-25 Methods and compositions for safe and effective treatment of erythema
US13/637,040 Abandoned US20130071489A1 (en) 2010-03-26 2011-03-25 Methods and compositions for safe and effective treatment of erythema
US13/456,976 Active US8513249B2 (en) 2010-03-26 2012-04-26 Methods and compositions for safe and effective treatment of erythema
US14/097,912 Abandoned US20140094469A1 (en) 2010-03-26 2013-12-05 Methods and compositions for safe and effective treatment of erythema
US14/679,598 Active US9861631B2 (en) 2010-03-26 2015-04-06 Methods and compositions for safe and effective treatment of erythema
US14/968,104 Active US9861632B2 (en) 2010-03-26 2015-12-14 Methods and compositions for safe and effective treatment of erythema

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/072,096 Active US8513247B2 (en) 2010-03-26 2011-03-25 Methods and compositions for safe and effective treatment of erythema

Family Applications After (4)

Application Number Title Priority Date Filing Date
US13/456,976 Active US8513249B2 (en) 2010-03-26 2012-04-26 Methods and compositions for safe and effective treatment of erythema
US14/097,912 Abandoned US20140094469A1 (en) 2010-03-26 2013-12-05 Methods and compositions for safe and effective treatment of erythema
US14/679,598 Active US9861631B2 (en) 2010-03-26 2015-04-06 Methods and compositions for safe and effective treatment of erythema
US14/968,104 Active US9861632B2 (en) 2010-03-26 2015-12-14 Methods and compositions for safe and effective treatment of erythema

Country Status (16)

Country Link
US (6) US8513247B2 (fr)
EP (1) EP2552449B1 (fr)
JP (1) JP5747391B2 (fr)
KR (3) KR20170018974A (fr)
CN (2) CN106038476B (fr)
AU (1) AU2011231543B2 (fr)
BR (1) BR112012024289A2 (fr)
CA (1) CA2792646C (fr)
DK (1) DK2552449T3 (fr)
ES (1) ES2627405T3 (fr)
HU (1) HUE033143T2 (fr)
MX (1) MX2012010824A (fr)
PL (1) PL2552449T3 (fr)
PT (1) PT2552449T (fr)
RU (1) RU2519676C1 (fr)
WO (1) WO2011117377A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513247B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
JP2013508454A (ja) * 2009-10-26 2013-03-07 ガルデルマ ファルマ ソシエテ アノニム 急性紅斑の治療又は予防法
AU2011273510B2 (en) * 2010-06-30 2015-04-16 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
EP2629757A2 (fr) 2010-10-21 2013-08-28 Galderma S.A. Compositions de gel de brimonidine et leurs procédés d'utilisation
EP2731606A1 (fr) * 2011-07-14 2014-05-21 Allergan, Inc. Compositions de gel d'oxymétazoline et leurs procédés d'utilisation
WO2013057579A2 (fr) 2011-10-19 2013-04-25 Galderma Pharma S.A. Méthode permettant de réduire les rougeurs du visage associées à l'utilisation systémique d'inhibiteurs de phosphodiestérases de type 5
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MX2021001645A (es) * 2018-08-29 2021-05-12 Cellix Bio Private Ltd Metodos y composiciones oftalmicas para el tratamiento de trastornos del ojo y enfermedades de la piel.
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US3560501A (en) 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
BG16042A3 (bg) 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3594380A (en) 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.
US3740442A (en) 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4164570A (en) 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2436882A1 (de) 1974-07-29 1976-02-19 Schering Ag Neue oxyphenylbutazon-derivate und ihre herstellung
DE2632678C2 (de) 1976-07-16 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 6α-Fluor-12α-Halogen-Kortikoide und Verfahren zu ihrer Herstellung
NZ185295A (en) 1976-10-04 1980-04-28 Schering Ag 9-chloroprednisolone derivatives and pharmaceutical compositions
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (fr) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Solutions ophtalmiques aqueuses et methode de conservation
FR2648709A1 (fr) 1989-06-23 1990-12-28 Boehringer Ingelheim France Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants
US5077292A (en) 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5326763A (en) 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5204347A (en) 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5112822A (en) 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5198442A (en) 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5237072A (en) 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
GB9010526D0 (en) 1990-05-10 1990-07-04 Unilever Plc Cosmetic composition
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
WO1995010280A1 (fr) 1993-10-13 1995-04-20 Allergan Modes d'utilisation de derives de la quinoxaline (2 - imidazolin - 2 - ylamino)
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6117871A (en) 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
WO1996013267A2 (fr) 1994-10-27 1996-05-09 Allergan Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
WO1996025163A1 (fr) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Traitement de virus de l'herpes
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (fr) 1995-07-28 1997-01-29 Kenneth T. Armstrong Preparation topique a base de phenylephrine
US5720962A (en) 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5916574A (en) 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US5910312A (en) 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
US5753637A (en) 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
JP2001512471A (ja) 1997-02-21 2001-08-21 バイヤースドルフ・アクチエンゲゼルシヤフト しゅさの処置のための調製物
US6007846A (en) 1997-05-16 1999-12-28 Townley Jewelry, Inc. Scented body gel having particulate matter in the form of glitter with predetermined shapes
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
US6159944A (en) 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
DE99907899T1 (de) 1998-03-11 2005-01-13 Kabushiki Kaisha Soken Hautnormalisierungsmittel
US6432934B1 (en) 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
ATE291907T1 (de) 1998-10-20 2005-04-15 Omeros Corp Spülende lösung und methoden zur hemmung von schmerzen und entzündungen
US20020197300A1 (en) 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
SE9901295D0 (sv) 1999-04-13 1999-04-13 Jan Hedner Sätt och medel för att förebygga, behandla och diagnostisera kardiovaskulära komplikationer hos patienter med obstruktiv sömnapné
AU5331200A (en) 1999-06-11 2001-01-02 Ohio State University Research Foundation, The Methods and compositions for treating raynaud's phenomenon and scleroderma
WO2001013955A1 (fr) 1999-08-19 2001-03-01 Lavipharm S.A. Polymeres filmogenes, procedes d'utilisation, et leurs dispositifs et applications
US6147102A (en) 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US6294553B1 (en) 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
BR0109317A (pt) 2000-07-14 2003-06-17 Allergan Inc Composições contendo componentes agonistas alfa-2-adrenérgicos
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
TNSN02063A1 (en) 2001-07-07 2005-12-23 Egyptian Natural Oil Co Natoil The medical effect of jojoba oil
US7115724B2 (en) 2001-08-22 2006-10-03 Wyeth Murine genomic polynucleotide sequence encoding a G-protein coupled receptor and methods of use therefor
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040092482A1 (en) 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en) 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en) 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
EP1622554A4 (fr) 2003-05-15 2008-01-02 Bioform Medical Inc Compositions contenant un melange d'un agent pharmaceutique ou d'un agent cosmetique et d'un aldehyde aromatique de support de groupe oxy
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050059664A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7285544B2 (en) 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8529927B2 (en) 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
EP2481412B1 (fr) * 2004-05-25 2017-09-27 Galderma Pharma S.A. Composés, formulations et procédés pour traiter ou prévenir les troubles inflammatoires de la peau
US20070003622A1 (en) 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
EP1841320A2 (fr) 2005-01-12 2007-10-10 S.U.L.V.E. Ltd. Procedes et compositions pharmaceutiques utilisees pour le traitement du psoriasis
EP1861356A1 (fr) 2005-02-01 2007-12-05 Icagen, Inc. Imines modulateurs du canal ionique
US20070082070A1 (en) 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
JP2009528382A (ja) 2006-03-01 2009-08-06 トリストラータ・インコーポレイテッド タール応答性皮膚疾患の局所治療のための組成物及び方法
US20070258935A1 (en) 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
WO2008074885A2 (fr) 2006-12-21 2008-06-26 Novagali Pharma Sa Procédé de fabrication d'émulsions ophtalmiques huile-dans-eau
DE102006062619B4 (de) 2006-12-29 2012-04-26 Medion Diagnostics Ag Verfahren zur Bestimmung von minoren Zellpopulationen in heterogenen Zellpopulationen
US20080293728A1 (en) 2007-05-18 2008-11-27 Mcintire Gregory L Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
SI2182960T1 (sl) 2007-07-27 2014-07-31 Galderma Laboratories Inc. Spojine, formulacije in postopki za zmanjĺ anje koĺ˝nih gub, meäśkanja in poveĺ anja
US20090061020A1 (en) 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
BRPI0819075A2 (pt) 2007-11-16 2014-10-07 Vicept Therapeutics Inc Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
US20110224215A1 (en) * 2007-12-21 2011-09-15 Galderma Laboratories, Inc. Pre-surgical treatment
EP2090307A1 (fr) 2008-02-15 2009-08-19 Bone Therapeutics Composition pharmaceutique pour le traitement ou la prévention de maladies ostéo-articulaires
AU2009251743A1 (en) * 2008-05-30 2009-12-03 Fairfield Clinical Trials, Llc Method and composition for skin inflammation and discoloration
WO2009158646A1 (fr) 2008-06-27 2009-12-30 Elixir Pharmaceuticals, Inc. Composés thérapeutiques et procédés d'utilisation apparentés
EP2320911B1 (fr) 2008-08-01 2014-10-08 Eye Therapies LLC Compositions de vasoconstriction, et procédés d'utilisation
US8268345B2 (en) 2008-09-03 2012-09-18 Transdermal Innovations Inc. Multipurpose hydrogel compositions and products
US20100196291A1 (en) 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
JP5052558B2 (ja) * 2009-04-03 2012-10-17 ロート製薬株式会社 ゲル軟膏
KR101453601B1 (ko) * 2009-05-29 2014-10-22 갈데르마 리써어치 앤드 디벨로프먼트 주입으로 인한 피부 반응 감소를 위한 필러와 아드레날린 수용체 작용제의 주사가능한 조합
JP2013508454A (ja) 2009-10-26 2013-03-07 ガルデルマ ファルマ ソシエテ アノニム 急性紅斑の治療又は予防法
LT2493474T (lt) 2009-10-30 2019-10-10 Intratus, Inc. Būdai ir kompozicijos prolonguotam vaistų įvedimui
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
AU2011231544B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
CN106038476B (zh) * 2010-03-26 2020-04-17 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
AU2011273510B2 (en) 2010-06-30 2015-04-16 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
US20120101104A1 (en) 2010-10-21 2012-04-26 Galderma S.A. Topical gel compositions and methods of use
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513247B2 (en) 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
US9861631B2 (en) 2010-03-26 2018-01-09 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US9861632B2 (en) 2010-03-26 2018-01-09 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema

Also Published As

Publication number Publication date
AU2011231543B2 (en) 2015-01-15
US20150209350A1 (en) 2015-07-30
US8513247B2 (en) 2013-08-20
KR101707704B1 (ko) 2017-02-16
KR20170018974A (ko) 2017-02-20
WO2011117377A3 (fr) 2013-01-10
WO2011117377A2 (fr) 2011-09-29
PL2552449T3 (pl) 2017-09-29
RU2519676C1 (ru) 2014-06-20
JP5747391B2 (ja) 2015-07-15
BR112012024289A2 (pt) 2017-07-18
US20120214816A1 (en) 2012-08-23
MX2012010824A (es) 2012-10-10
AU2011231543A1 (en) 2012-09-27
ES2627405T3 (es) 2017-07-28
KR20130002338A (ko) 2013-01-07
US20160095857A1 (en) 2016-04-07
US20110286944A1 (en) 2011-11-24
CN106038476B (zh) 2020-04-17
DK2552449T3 (en) 2017-06-19
JP2013523611A (ja) 2013-06-17
CN106038476A (zh) 2016-10-26
HUE033143T2 (en) 2017-11-28
US8513249B2 (en) 2013-08-20
US9861631B2 (en) 2018-01-09
EP2552449B1 (fr) 2017-04-19
CA2792646A1 (fr) 2011-09-29
PT2552449T (pt) 2017-06-12
KR20150055082A (ko) 2015-05-20
EP2552449A2 (fr) 2013-02-06
RU2012145616A (ru) 2014-05-10
CA2792646C (fr) 2018-11-20
US9861632B2 (en) 2018-01-09
CN103298472A (zh) 2013-09-11
US20140094469A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
US9861632B2 (en) Methods and compositions for safe and effective treatment of erythema
US20170296535A1 (en) Methods and compositions for treating or preventing erythema
US8916562B2 (en) Methods and compositions for safe and effective treatment of telangiectasia
AU2016269419A1 (en) Improved methods and compositions for safe and effective treatment of erythema
AU2015201750A1 (en) Improved methods and compositions for safe and effective treatment of erythema

Legal Events

Date Code Title Description
AS Assignment

Owner name: GALDERMA RESEARCH & DEVELOPMENT SNC, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRAEBER, MICHAEL;LOESCHE, CHRISTIAN;FREIDENREICH, PHILIP;AND OTHERS;SIGNING DATES FROM 20121003 TO 20121022;REEL/FRAME:029284/0411

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION